'$BCLI NurOwn for ALS. In the phase 2, there was no difference from placebo on ALSFRS scale. In fact, by 12 weeks follow-up, placebo patients were progressing slower. But sure, make a profit on RTT patients.' - -tweet from STAT News' Adam F
Benzinga Newsdesk